Scienture Holdings (SCNX) said Tuesday it has formalized a commercial Pharmacy Benefit Manager led Group Purchasing Organization rebate agreement.

This agreement involves negotiating rebates with pharmaceutical manufacturers on behalf of a group of buyers, such as employers, insurers or health care plans.

The agreement is expected to both expand patient access and reduce reimbursement barriers, the company said.

The company said this pact is for advancing the process of securing formulary access with health plans covering more than 100 million people for Arbli (losartan potassium) Oral Suspension, 10 mg/mL.

According to Scienture Holdings, Arbli is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes.

It further added that additional discussions are underway to further expand both commercial and government coverage for the product.